Radiation for Triple-Negative Breast Cancer: 84 Real Stories

84 stories match breast cancer, triple-negative and radiation. 82 of them mention surgery.

Cancer Stories

Anne, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Triple-Negative Breast Cancer: Anne's Survivor Story

Patient Info: Anne, Female | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Anne completed chemotherapy during pregnancy, double mastectomy, radiotherapy, and additional chemotherapy for Stage III metaplastic triple-negative breast cancer and described using the experience as a source of personal transformation.

breastcancer.org
OutcomeSurvivorship / Completed Treatment
Toni, who was diagnosed with Breast CancerBreast Cancer

HR-Positive Breast Cancer: Toni's Patient Story

Patient Info: Toni S, Female, 50s

Biomarkers: ER-positive or PR-positive; HER2-positive; triple-positive breast cancer

Toni completed chemotherapy, surgery, Kadcyla, and radiation for triple-positive breast cancer with lymph-node involvement and continued anastrozole to suppress estrogen.

BreastCancer.org (ES)
OutcomeCare Ongoing
Stephanie, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II BRCA1 Invasive Ductal Carcinoma: Stephanie's Patient Story

Patient Info: Stephanie Hargis, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

Stephanie had Stage II triple-negative breast cancer with BRCA1 mutation, then a local recurrence in April 2023 without distant spread; after surgery, chemotherapy, Keytruda, radiation, and Lynparza, she remained in ongoing post-recurrence treatment.

BreastCancer.org (ES)
OutcomeCare Ongoing
Valerie, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Valerie's Survivor Story

Patient Info: Valerie Hamilton, Female, 50s | Stage Metastatic/Advanced

Biomarkers: Triple-negative breast cancer; ER-negative; PR-negative; HER2-negative

Valerie completed chemotherapy, lumpectomy and radiation for locally advanced triple-negative breast cancer and preserved her breast/body image; no explicit NED or cancer-free status was provided.

Memorial Sloan Kettering
OutcomeSurvivorship / Surveillance
Alison, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient Story
OutcomeLiving With Cancer / Remission
Stefanie, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage III HR-Positive Invasive Ductal Carcinoma: Stefanie's Survivor Story

Patient Info: Stefanie, Female | Stage III

Biomarkers: ER-positive, PR-positive and HER2-positive

Stefanie completed chemotherapy, breast-conserving surgery, prolonged Herceptin and 30 radiation treatments, then moved into survivorship while still adjusting to the lasting effects of treatment.

The Patient Story
OutcomeTreatment Completed / Survivorship
Shari, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient Story
OutcomeLiving With Cancer / Ongoing Therapy
Lucy, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Triple-Negative Breast Cancer: Lucy's Survivor Story

Patient Info: Lucy, Female, Under 40 | Stage II

Biomarkers: Germline BRCA1 mutation; triple-negative breast cancer

Surgical pathology was all clear on June 17 after a strong chemotherapy response. Lucy described herself as cancer-free and continued oncology reviews every 3–4 months while planning delayed reconstruction.

The Patient Story
OutcomeCancer-Free / NED, Surveillance
Erin, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Triple-Negative Breast Cancer: Erin's Patient Story

Patient Info: Erin, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; later tumor responded to androgen signaling

Metastatic Site: Lung; brain

As of June 2026, Erin was living with metastatic triple-negative breast cancer involving lung and brain, with tumors shrinking on ongoing Gemzar plus carboplatin chemotherapy every 2 weeks.

The Patient Story
OutcomeResponding Well
Doreen, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Doreen's Patient Story

Patient Info: Doreen, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Doreen had completed TCHP chemotherapy with a complete response before surgery and had undergone lumpectomy and radiation for Stage IIA triple-positive breast cancer.

The Patient Story
OutcomeResponding Well
Marina, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Marina's Survivor Story

Patient Info: Marina, Female, Under 40

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Triple-negative breast cancer survivor with a BRCA1 mutation who completed treatment after an initial diagnosis and a second diagnosis at the 5-year mark; no formal stage or metastatic disease was stated in the available source text.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Jacqueline, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Jacqueline's Patient Story

Patient Info: Jacqueline Bennett, Female, Under 40

Biomarkers: Initial ER-negative, PR-negative, HER2-negative; later HER2-positive

Jacqueline completed treatment for initial Stage IA triple-negative breast cancer during pregnancy and later developed a HER2-positive, hormone receptor-negative breast cancer. After 3 of 6 current treatments, the tumor was no longer visible on ultrasound or MRI, with targeted therapy and double mastectomy still planned.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Breast CancerBreast Cancer

Triple-negative breast cancer diagnosed during pregnancy: remission

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

The patient remains in remission 30 months after surgery. Immune-related brachial plexopathy after treatment improved after steroids, IVIG, and plasmapheresis, with electrophysiologic resolution and near-complete strength and sensory recovery.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast Squamous Cell CarcinomaBreast Cancer

Non-metastatic metaplastic triple-negative breast cancer with residual disease after chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Metaplastic triple-negative breast cancer; HER2 0

The patient had an initial partial response to neoadjuvant chemotherapy but then progressed before surgery. Modified radical mastectomy found substantial residual metaplastic carcinoma with 0/21 nodes involved, followed by adjuvant radiotherapy and metronomic capecitabine.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage IIIB triple-negative metaplastic breast cancer: urgent mastectomy and reconstruction after rapid progression on neoadjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; nuclear grade 3

At 18-month follow-up, she was disease-free after urgent mastectomy, axillary dissection, flap/skin-graft reconstruction, resumed chemotherapy, and radiation for rapidly progressive triple-negative metaplastic breast cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 breast cancer: 4 years and counting

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor: hormone receptor-positive; HER2 1+. Metastatic recurrence: triple-negative breast cancer.

Metastatic Site: liver, bone, lung, supraclavicular lymph nodes,…

After response of choroidal metastases to eye radiation plus sacituzumab govitecan, disease progressed in February 2023 with cerebellar and pituitary brain lesions; she developed obstructive hydrocephalus, entered hospice in May 2023, and died in June 2023.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic triple-negative breast cancer with sacituzumab-govitecan pneumonitis and progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lung

Sacituzumab-govitecan pneumonitis improved with corticosteroids and half-dose rechallenge did not reproduce pneumonitis, but follow-up CT showed one new pulmonary metastasis and enlargement of previous lung metastases; PFS on sacituzumab govitecan was 5.37 months.

PubMed Central
OutcomeSetback / Progression
Chase, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Triple-Negative Breast Cancer: Chase's Survivor Story

Patient Info: Chase, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative

As of January 2026, Chase had shown no evidence of cancer for nearly 5 years after Stage IIB triple-negative breast cancer treatment and had completed 3 investigational vaccine injections without significant side effects.

Cleveland Clinic
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Stage IV triple-negative invasive lobular breast cancer with HER2 mutations: complete metabolic response to trastuzumab deruxtecan

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Triple-negative invasive lobular breast cancer with HER2-low/dubious staining and HER2 FISH-negative; somatic ERBB2/HER2 and mutations.

Metastatic Site: iliac bone lesions / bone metastases

As of January 2026, metastatic triple-negative invasive lobular breast cancer with HER2 mutations had a sustained complete metabolic response to trastuzumab deruxtecan for 20 months, with dose reduction for neutropenia and no pulmonary toxicity.

PubMed Central
OutcomeResponding Well
Sian, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Sian's Survivor Story

Patient Info: Sian Bevans, Female, 50s | Stage II

Biomarkers: Triple-positive

Sian was 11 years past diagnosis, completed 10 years of maintenance medication in May 2025, and reported feeling more like herself; no recurrence was described.

Cleveland Clinic
OutcomeSurvivorship / Completed Treatment
Janella, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Janella's Survivor Story

Patient Info: Janella Bustamante, Female, 40s

Biomarkers: Triple-positive: estrogen-, progesterone- and HER2-fueled breast cancer

As of October 2025, Janella had completed lumpectomy, chemotherapy, radiation and HER2-targeted biological therapy for triple-positive breast cancer and was on follow-up every 3 months; the source describes life after cancer but does not explicitly state NED/cancer-free.

Cleveland Clinic
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Breast CancerBreast Cancer

PT2N0M0 breast malignant adenomyoepithelioma: disease-free after excision and radiation

Patient Info: Anonymized, Female, 50s

Biomarkers: p63-positive; E-cadherin-positive; CK7-negative on pathology re-review; ER-negative; PR-negative; HER2/neu-negative; sentinel lymph node negative, triple negative

Alive with no evidence of disease after 78 months of follow-up following wide local excision and adjuvant breast radiation.

PubMed Central
OutcomeCancer-Free / NED
Jennifer, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Njathi, Female, 40s | Stage II

Biomarkers: Triple-positive; ER-positive; PR-positive; HER2-positive

As of October 2025, Jennifer was more than 1 year past treatment for triple-positive Stage IIA breast cancer and had a recent clear MRI.

City of Hope
OutcomeCancer-Free / NED